{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:15:00Z","timestamp":1757700900791,"version":"3.37.3"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1208\/s12249-021-02008-8","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T15:03:19Z","timestamp":1619794999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Formulation, Pharmacokinetics evaluation, and IVIVC Assessment of Gliclazide Multiparticulates in Rat Model"],"prefix":"10.1208","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7442-6133","authenticated-orcid":false,"given":"Ahmed A.","family":"El-Ashmawy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya R.","family":"Abdou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nesrin F.","family":"Taha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebtesam W.","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled M.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila H.","family":"Emara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"issue":"1","key":"2008_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1208\/s12249-009-9191-8","volume":"10","author":"J Varshosaz","year":"2009","unstructured":"Varshosaz J, Tavakoli N, Minayian M, Rahdari N. Applying the Taguchi design for optimized formulation of sustained release gliclazide chitosan beads: an in vitro\/in vivo study. AAPS PharmSciTech. 2009;10(1):158\u201365. https:\/\/doi.org\/10.1208\/s12249-009-9191-8.","journal-title":"AAPS PharmSciTech."},{"key":"2008_CR2","doi-asserted-by":"crossref","unstructured":"Rajabi-Siahboomi AR. Multiparticulate drug delivery: formulation, processing and manufacturing: Springer; 2017.","DOI":"10.1007\/978-1-4939-7012-4"},{"issue":"12","key":"2008_CR3","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.3109\/03639045.2014.917657","volume":"40","author":"D Jain","year":"2014","unstructured":"Jain D, Bar-Shalom D. Alginate drug delivery systems: application in context of pharmaceutical and biomedical research. Drug Dev Ind Pharm. 2014;40(12):1576\u201384. https:\/\/doi.org\/10.3109\/03639045.2014.917657.","journal-title":"Drug Dev Ind Pharm."},{"issue":"9","key":"2008_CR4","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1517\/17425247.2015.1037272","volume":"12","author":"M Foox","year":"2015","unstructured":"Foox M, Zilberman M. Drug delivery from gelatin-based systems. Expert Opin Drug Deliv. 2015;12(9):1547\u201363. https:\/\/doi.org\/10.1517\/17425247.2015.1037272.","journal-title":"Expert Opin Drug Deliv."},{"issue":"1","key":"2008_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0378-5173(98)00167-7","volume":"172","author":"F G\u0142\u00f3wka","year":"1998","unstructured":"G\u0142\u00f3wka F, Hermann T, Zabel M. Bioavailability of gliclazide from some formulation tablets. Int J Pharm. 1998;172(1):71\u20137. https:\/\/doi.org\/10.1016\/S0378-5173(98)00167-7.","journal-title":"Int J Pharm."},{"issue":"3","key":"2008_CR6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3109\/03639045.2013.763817","volume":"40","author":"R Awasthi","year":"2014","unstructured":"Awasthi R, Kulkarni GT. Development of novel gastroretentive drug delivery system of gliclazide: hollow beads. Drug Dev Ind Pharm. 2014;40(3):398\u2013408. https:\/\/doi.org\/10.3109\/03639045.2013.763817.","journal-title":"Drug Dev Ind Pharm."},{"issue":"2","key":"2008_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1208\/s12249-018-1214-x","volume":"20","author":"P Patel","year":"2019","unstructured":"Patel P, Pailla SR, Rangaraj N, Cheruvu HS, Dodoala S, Sampathi S. Quality by design approach for developing lipid-based nanoformulations of gliclazide to improve oral bioavailability and anti-diabetic activity. AAPS PharmSciTech. 2019;20(2):45. https:\/\/doi.org\/10.1208\/s12249-018-1214-x.","journal-title":"AAPS PharmSciTech."},{"issue":"1","key":"2008_CR8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2165\/00003495-199346010-00007","volume":"46","author":"KJ Palmer","year":"1993","unstructured":"Palmer KJ, Brogden RN. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs. 1993;46(1):92\u2013125. https:\/\/doi.org\/10.2165\/00003495-199346010-00007.","journal-title":"Drugs."},{"issue":"2","key":"2008_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1046\/j.1365-2125.2003.01751.x","volume":"55","author":"N Frey","year":"2003","unstructured":"Frey N, Laveille C, Paraire M, Francillard M, Holford NH, Jochemsen R. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. Br J Clin Pharmacol. 2003;55(2):147\u201357. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.01751.x.","journal-title":"Br J Clin Pharmacol."},{"issue":"4","key":"2008_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/bdd.303","volume":"23","author":"P Delrat","year":"2002","unstructured":"Delrat P, Paraire M, Jochemsen R. Complete bioavailability and lack of food effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers. Biopharm Drug Dispos. 2002;23(4):151\u20137. https:\/\/doi.org\/10.1002\/bdd.303.","journal-title":"Biopharm Drug Dispos."},{"issue":"5","key":"2008_CR11","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2165\/00003088-197904050-00003","volume":"4","author":"DE Rollins","year":"1979","unstructured":"Rollins DE, Klaassen CD. Biliary excretion of drugs in man. Clinical Pharmacokinetics. 1979;4(5):368\u201379. https:\/\/doi.org\/10.2165\/00003088-197904050-00003.","journal-title":"Clinical Pharmacokinetics."},{"issue":"2","key":"2008_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0168-3659(97)00167-3","volume":"51","author":"SS Hong","year":"1998","unstructured":"Hong SS, Lee SH, Lee YJ, Chung SJ, Lee MH, Shim CK. Accelerated oral absorption of gliclazide in human subjects from a soft gelatin capsule containing a PEG 400 suspension of gliclazide. J Control Release. 1998;51(2):185\u201392. https:\/\/doi.org\/10.1016\/S0168-3659(97)00167-3.","journal-title":"J Control Release."},{"issue":"3","key":"2008_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1046\/j.1365-2125.2000.00162.x","volume":"49","author":"TM Davis","year":"2000","unstructured":"Davis TM, Daly F, Walsh JP, Ilett KF, Beilby JP, Dusci LJ, et al. Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes. Br J Clin Pharmacol. 2000;49(3):223\u201330. https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00162.x.","journal-title":"Br J Clin Pharmacol."},{"key":"2008_CR14","first-page":"57","volume-title":"Gliclazide and Treatment of Diabetes","author":"A Benakis","year":"1980","unstructured":"Benakis A, Glasson B. Metabolic study of 14 C-labelled gliclazide in normal rats and in rats with streptozotocin-induced diabetes. In: Keen H, editor. Gliclazide and Treatment of Diabetes. London: Academic Press and the Royal Society of Medicine; 1980. p. 57\u201369."},{"issue":"2","key":"2008_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/BF03188737","volume":"8","author":"H Miyazaki","year":"1983","unstructured":"Miyazaki H, Fujii T, Yoshida K, Arakawa S, Furukawa H, Suzuki H, et al. Disposition and metabolism of [3H]gliclazide in rats. Eur J Drug Metab Pharmacokinet. 1983;8(2):117\u201331. https:\/\/doi.org\/10.1007\/BF03188737.","journal-title":"Eur J Drug Metab Pharmacokinet."},{"issue":"4","key":"2008_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1586\/14750708.4.4.457","volume":"4","author":"S Satyanarayana","year":"2007","unstructured":"Satyanarayana S, Kumar KE, Rajasekhar J, Thomas L, Rajanna S, Rajanna B. Influence of aqueous extract of fenugreek-seed powder on the pharmacodynamics and pharmacokinetics of gliclazide in rats\/rabbits. Therapy. 2007;4(4):457\u201363. https:\/\/doi.org\/10.1586\/14750708.4.4.457.","journal-title":"Therapy."},{"issue":"3","key":"2008_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.22377\/ajp.v2i3.209","volume":"2","author":"TGK Murthy","year":"2008","unstructured":"Murthy TGK, Mayuren C. Influence of calcium channel antagonist on the pharmacodynamics of a second-generation sulfonylurea in rats and rabbits. Asian J Pharm. 2008;2(3):163\u20136. https:\/\/doi.org\/10.22377\/ajp.v2i3.209.","journal-title":"Asian J Pharm"},{"issue":"1","key":"2008_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3923\/crcpaj.2017.22.28","volume":"6","author":"ARN Reddy","year":"2017","unstructured":"Reddy ARN, Kumar BV. Effect of valsartan on pharmacokinetics and pharmacodynamics of gliclazide in diabetic rats. Curr Res Cardiovasc Pharmacol. 2017;6(1):22\u20138. https:\/\/doi.org\/10.3923\/crcpaj.2017.22.28.","journal-title":"Curr Res Cardiovasc Pharmacol"},{"issue":"1","key":"2008_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5937\/scriptamed51-25521","volume":"51","author":"J Jovi\u0107","year":"2020","unstructured":"Jovi\u0107 J, Milija\u0161evi\u0107 B, Vukmirovi\u0107 S, Vasovi\u0107 V, Mikov M, Mooranian A, et al. Pharmacokinetic and drug absorption profiles of the anti-hyperglycaemic agent gliclazide in oral tissue-targeted microcapsules in rats. Scripta Medica. 2020;51(1):15\u201320. https:\/\/doi.org\/10.5937\/scriptamed51-25521.","journal-title":"Scripta Medica."},{"issue":"12","key":"2008_CR20","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1080\/03639045.2019.1689992","volume":"45","author":"EW Elsayed","year":"2019","unstructured":"Elsayed EW, El-Ashmawy AA, Mursi NM, Emara LH. Optimization of gliclazide loaded alginate-gelatin beads employing central composite design. Drug Dev Ind Pharm. 2019;45(12):1959\u201372. https:\/\/doi.org\/10.1080\/03639045.2019.1689992.","journal-title":"Drug Dev Ind Pharm."},{"key":"2008_CR21","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2147\/IJN.S235290","volume":"15","author":"AM Nazief","year":"2020","unstructured":"Nazief AM, Hassaan PS, Khalifa HM, Sokar MS, El-Kamel AH. Lipid-based gliclazide nanoparticles for treatment of diabetes: formulation, pharmacokinetics, pharmacodynamics and subacute toxicity study. Int J Nanomedicine. 2020;15:1129\u201348. https:\/\/doi.org\/10.2147\/IJN.S235290.","journal-title":"Int J Nanomedicine."},{"issue":"1","key":"2008_CR22","doi-asserted-by":"publisher","first-page":"17331","DOI":"10.1038\/s41598-019-53996-4","volume":"9","author":"BP Panda","year":"2019","unstructured":"Panda BP, Krishnamoorthy R, Bhattamisra SK, Shivashekaregowda NKH, Seng LB, Patnaik S. Fabrication of second generation smarter PLGA based nanocrystal carriers for improvement of drug delivery and therapeutic efficacy of gliclazide in type-2 diabetes rat model. Sci Rep. 2019;9(1):17331. https:\/\/doi.org\/10.1038\/s41598-019-53996-4.","journal-title":"Sci Rep."},{"key":"2008_CR23","volume-title":"Pharmacokinetics and metabolism of gliclazide: a review. Gliclazide and the treatment of diabetes","author":"D Campbell","year":"1980","unstructured":"Campbell D, Adriaenssens P, Hopkins Y, Gordon B, Williams J. Pharmacokinetics and metabolism of gliclazide: a review. Gliclazide and the treatment of diabetes. London: Royal Society of Medicine; 1980."},{"issue":"5","key":"2008_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/bdd.310","volume":"23","author":"N Najib","year":"2002","unstructured":"Najib N, Idkaidek N, Beshtawi M, Bader M, Admour I, Alam SM, et al. Bioequivalence evaluation of two brands of gliclazide 80 mg tablets (Glyzide\u00ae & Diamicron\u00ae) \u2014 in healthy human volunteers. Biopharm Drug Dispos. 2002;23(5):197\u2013202. https:\/\/doi.org\/10.1002\/bdd.310.","journal-title":"Biopharm Drug Dispos."},{"issue":"7","key":"2008_CR25","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/bf02976882","volume":"26","author":"H Kim","year":"2003","unstructured":"Kim H, Yun M, Kwon KI. Pharmacokinetic and pharmacodynamic characterization of gliclazide in healthy volunteers. Arch Pharm Res. 2003;26(7):564\u20138. https:\/\/doi.org\/10.1007\/bf02976882.","journal-title":"Arch Pharm Res."},{"issue":"1","key":"2008_CR26","first-page":"29","volume":"13","author":"M Resztak","year":"2014","unstructured":"Resztak M, Hermann T, Sawicki W, Danielak D. Pharmacokinetics and pharmacodynamics of gliclazide from immediate and modified release formulation tablets in rats. Iran J Pharm Res. 2014;13(1):29\u201337.","journal-title":"Iran J Pharm Res."},{"issue":"2","key":"2008_CR27","first-page":"692","volume":"6","author":"L Adhikar","year":"2014","unstructured":"Adhikar L, Mishra U, Murthy P. RP-HPLC determination of gliclazide in rat plasma and its application in pharmacokinetic studies. Int J Pharmtech Res. 2014;6(2):692\u2013700 Unavailable.","journal-title":"Int J Pharmtech Res"},{"issue":"3","key":"2008_CR28","first-page":"388","volume":"59","author":"R Talari","year":"2011","unstructured":"Talari R, Varshosaz J, Mostafavi A, Nokhodchi A. Development and validation of a novel RP-HPLC method for pharmacokinetic studies of gliclazide in rat. Farmacia. 2011;59(3):388\u201395.","journal-title":"Farmacia."},{"issue":"2","key":"2008_CR29","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1208\/s12249-010-9441-9","volume":"11","author":"R Talari","year":"2010","unstructured":"Talari R, Varshosaz J, Mostafavi SA, Nokhodchi A. Gliclazide microcrystals prepared by two methods of in situ micronization: pharmacokinetic studies in diabetic and normal rats. AAPS PharmSciTech. 2010;11(2):786\u201392. https:\/\/doi.org\/10.1208\/s12249-010-9441-9.","journal-title":"AAPS PharmSciTech."},{"key":"2008_CR30","unstructured":"Elsayed EWH. Pharmaceutical studies on controlled release per-oral delivery systems for poorly soluble antidiabetic drug. CU Theses. 2017."},{"key":"2008_CR31","doi-asserted-by":"crossref","unstructured":"Elsayed EW, El-Ashmawy AA, Mahmoud KM, Mursi NM, Emara LH. Modulating gliclazide release and bioavailability utilizing multiparticulate drug delivery systems. J Pharm Innov. 2021; Accepted manuscripte 3.2.2021.","DOI":"10.1007\/s12247-021-09542-9"},{"issue":"2","key":"2008_CR32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejpb.2006.07.014","volume":"65","author":"MG Sankalia","year":"2007","unstructured":"Sankalia MG, Mashru RC, Sankalia JM, Sutariya VB. Reversed chitosan\u2013alginate polyelectrolyte complex for stability improvement of alpha-amylase: optimization and physicochemical characterization. Eur J Pharm Biopharm. 2007;65(2):215\u201332. https:\/\/doi.org\/10.1016\/j.ejpb.2006.07.014.","journal-title":"Eur J Pharm Biopharm."},{"issue":"6","key":"2008_CR33","first-page":"64","volume":"20","author":"JW Moore","year":"1996","unstructured":"Moore JW, Flanner HH. Mathematical comparison of curves with an emphasis on in-vitro dissolution profiles. Pharm Tech. 1996;20(6):64\u201374 Unavailable.","journal-title":"Pharm Tech"},{"key":"2008_CR34","unstructured":"Bolton S. Appendix IV. In: Swarbrick J, editor. Pharmaceutical statistics: practical and clinical applications. 3rd ed: Marcel Dekker, Inc.; 1997."},{"issue":"2","key":"2008_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4103\/0976-500X.72350","volume":"1","author":"S Parasuraman","year":"2010","unstructured":"Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. J Pharmacol Pharmacother. 2010;1(2):87\u201393. https:\/\/doi.org\/10.4103\/0976-500X.72350.","journal-title":"J Pharmacol Pharmacother."},{"key":"2008_CR36","unstructured":"Taha NF, Elsayed EW, El-Ashmawy AA, Abdou AR, Emara LH. Impact of sample storage conditions on gliclazide quantification in rat plasma by UHPLC\/UV method: storage recommendation and pharmacokinetic application. J App Pharm Sci. 2021; Accepted manuscript."},{"key":"2008_CR37","doi-asserted-by":"publisher","unstructured":"Shaik M, Shaik S, Kilari EK. Population pharmacokinetics of gliclazide in normal and diabetic rabbits. 2018;39(5):265\u201374. https:\/\/doi.org\/10.1002\/bdd.2132.","DOI":"10.1002\/bdd.2132"},{"key":"2008_CR38","doi-asserted-by":"publisher","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc.; 1982.","edition":"2"},{"key":"2008_CR39","unstructured":"FDA. Guidance for Industry, Statistical Approaches to Establishing Bioequivalence, Docket No. 01D-0027.: Center for Drug Evaluation and Research (CDER), Rockville, MD 20857, USA.; 2001 [Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/statistical-approaches-establishing-bioequivalence, Accessed on 10 March 2021."},{"issue":"8","key":"2008_CR40","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1080\/03639045.2020.1791164","volume":"46","author":"NF Taha","year":"2020","unstructured":"Taha NF, Emam MF, Emara LH. A novel combination of Soluplus\u00ae\/Poloxamer for Meloxicam solid dispersions via hot melt extrusion for rapid onset of action. Part 2: comparative bioavailability and IVIVC. Drug Dev Ind Pharm. 2020;46(8):1362\u201372. https:\/\/doi.org\/10.1080\/03639045.2020.1791164.","journal-title":"Drug Dev Ind Pharm."},{"issue":"5","key":"2008_CR41","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1208\/s12249-014-0140-9","volume":"15","author":"P Pankongadisak","year":"2014","unstructured":"Pankongadisak P, Ruktanonchai UR, Supaphol P, Suwantong O. Preparation and characterization of silver nanoparticles-loaded calcium alginate beads embedded in gelatin scaffolds. AAPS PharmSciTech. 2014;15(5):1105\u201315. https:\/\/doi.org\/10.1208\/s12249-014-0140-9.","journal-title":"AAPS PharmSciTech."},{"issue":"6","key":"2008_CR42","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1007\/s10570-013-0048-7","volume":"20","author":"J-Y Kim","year":"2013","unstructured":"Kim J-Y, S-h K, Rhee Y-S, Park C-W, Park E-S. Preparation of hydroxypropylmethyl cellulose-based porous matrix for gastroretentive delivery of gabapentin using the freeze-drying method. Cellulose. 2013;20(6):3143\u201354. https:\/\/doi.org\/10.1007\/s10570-013-0048-7.","journal-title":"Cellulose."},{"issue":"2","key":"2008_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1590\/S0100-46702004000200009","volume":"29","author":"J Soares","year":"2004","unstructured":"Soares J, Santos J, Chierice G, Cavalheiro E. Thermal behavior of alginic acid and its sodium salt. Ecl\u00e9tica Qu\u00edmica. 2004;29(2):57\u201364. https:\/\/doi.org\/10.1590\/S0100-46702004000200009.","journal-title":"Ecl\u00e9tica Qu\u00edmica."},{"issue":"2","key":"2008_CR44","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.carres.2007.10.016","volume":"343","author":"D Leal","year":"2008","unstructured":"Leal D, Matsuhiro B, Rossi M, Caruso F. FT-IR spectra of alginic acid block fractions in three species of brown seaweeds. Carbohydrate Research. 2008;343(2):308\u201316. https:\/\/doi.org\/10.1016\/j.carres.2007.10.016.","journal-title":"Carbohydrate Research."},{"issue":"3","key":"2008_CR45","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.foodchem.2003.09.038","volume":"86","author":"JH Muyonga","year":"2004","unstructured":"Muyonga JH, Cole CGB, Duodu KG. Fourier transform infrared (FTIR) spectroscopic study of acid soluble collagen and gelatin from skins and bones of young and adult Nile perch (Lates niloticus). Food Chemistry. 2004;86(3):325\u201332. https:\/\/doi.org\/10.1016\/j.foodchem.2003.09.038.","journal-title":"Food Chemistry."},{"issue":"11","key":"2008_CR46","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1080\/10601325.2012.722854","volume":"49","author":"N Devi","year":"2012","unstructured":"Devi N, Hazarika D, Deka C, Kakati D. Study of complex coacervation of gelatin A and sodium alginate for microencapsulation of olive oil. J Macromol Sci A. 2012;49(11):936\u201345. https:\/\/doi.org\/10.1080\/10601325.2012.722854.","journal-title":"J Macromol Sci A."},{"key":"2008_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep04706","volume":"4","author":"Q Xing","year":"2014","unstructured":"Xing Q, Yates K, Vogt C, Qian Z, Frost MC, Zhao F. Increasing mechanical strength of gelatin hydrogels by divalent metal ion removal. Sci Rep. 2014;4:1\u201310. https:\/\/doi.org\/10.1038\/srep04706.","journal-title":"Sci Rep."},{"issue":"1","key":"2008_CR48","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0168-3659(94)00076-7","volume":"33","author":"AC Hodsdon","year":"1995","unstructured":"Hodsdon AC, Mitchell JR, Davies MC, Melia CD. Structure and behaviour in hydrophilic matrix sustained release dosage forms: 3. The influence of pH on the sustained-release performance and internal gel structure of sodium alginate matrices. J Control Release. 1995;33(1):143\u201352. https:\/\/doi.org\/10.1016\/0168-3659(94)00076-7.","journal-title":"J Control Release."},{"issue":"3","key":"2008_CR49","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jconrel.2004.03.015","volume":"97","author":"PF Almeida","year":"2004","unstructured":"Almeida PF, Almeida A. Cross-linked alginate\u2013gelatine beads: a new matrix for controlled release of pindolol. J Control Release. 2004;97(3):431\u20139. https:\/\/doi.org\/10.1016\/j.jconrel.2004.03.015.","journal-title":"J Control Release."},{"issue":"1","key":"2008_CR50","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ijpharm.2007.03.047","volume":"341","author":"RS Al-Kassas","year":"2007","unstructured":"Al-Kassas RS, Al-Gohary O, Al-Faadhel MM. Controlling of systemic absorption of gliclazide through incorporation into alginate beads. Int J Pharm. 2007;341(1):230\u20137. https:\/\/doi.org\/10.1016\/j.ijpharm.2007.03.047.","journal-title":"Int J Pharm."},{"issue":"1","key":"2008_CR51","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1208\/s12249-010-9573-y","volume":"12","author":"S Grbic","year":"2011","unstructured":"Grbic S, Parojcic J, Ibric S, Djuric Z. In vitro\u2013in vivo correlation for gliclazide immediate-release tablets based on mechanistic absorption simulation. AAPS PharmSciTech. 2011;12(1):165\u201371. https:\/\/doi.org\/10.1208\/s12249-010-9573-y.","journal-title":"AAPS PharmSciTech."},{"key":"2008_CR52","unstructured":"British Pharmacopoeia. Appendix XII B; Dissolution. Ph Eur method (29 3). IV. London 2011."},{"key":"2008_CR53","unstructured":"FDA. CVM GFI #35 Bioequivalence Guidance, Docket No. 94D-0401: Center for Veterinary Medicine (CVM), Rockville, MD 20852, USA 2006 [Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-35-bioequivalence-guidance. Accessed on 10 March 2021."},{"issue":"2","key":"2008_CR54","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/s1734-1140(10)70277-2","volume":"62","author":"T Grabowski","year":"2010","unstructured":"Grabowski T, Jaroszewski JJ, Jakubowski P. Residual fraction of the area under the curve as a qualitative criterion in pharmacokinetic studies. Pharmacol Rep. 2010;62(2):374\u201382. https:\/\/doi.org\/10.1016\/s1734-1140(10)70277-2.","journal-title":"Pharmacol Rep."},{"key":"2008_CR55","unstructured":"R J. Extrapolating AUC to Infinity 2021 [https:\/\/www.certara.com\/knowledge-base\/extrapolating-auc-to-infinity\/. Accessed on 10 March 2021]."},{"issue":"2","key":"2008_CR56","first-page":"692","volume":"6","author":"L Adhikar","year":"2014","unstructured":"Adhikar L, Mishra U, Murthy P. RP-HPLC determination of gliclazide in rat plasma and its application in pharmacokinetic studies. International Journal of Pharm Tech Research. 2014;6(2):692\u2013700.","journal-title":"International Journal of Pharm Tech Research."},{"issue":"12","key":"2008_CR57","doi-asserted-by":"publisher","first-page":"5040","DOI":"10.1002\/jps.22209","volume":"99","author":"M Ostrowski","year":"2010","unstructured":"Ostrowski M, Wilkowska E, Baczek T. The influence of averaging procedure on the accuracy of IVIVC predictions: immediate release dosage form case study. Journal of pharmaceutical sciences. 2010;99(12):5040\u20135. https:\/\/doi.org\/10.1002\/jps.22209.","journal-title":"Journal of pharmaceutical sciences."},{"issue":"9","key":"2008_CR58","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/chromsci\/bmw106","volume":"54","author":"A Hanafy","year":"2016","unstructured":"Hanafy A, Mahgoub H. A validated HPLC Method for the determination of linagliptin in rat plasma. Application to a pharmacokinetic study. J Chromatogr Sci. 2016;54(9):1573\u20137. https:\/\/doi.org\/10.1093\/chromsci\/bmw106.","journal-title":"J Chromatogr Sci."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-021-02008-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-021-02008-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-021-02008-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T13:05:23Z","timestamp":1621861523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-021-02008-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["2008"],"URL":"https:\/\/doi.org\/10.1208\/s12249-021-02008-8","relation":{},"ISSN":["1530-9932"],"issn-type":[{"type":"electronic","value":"1530-9932"}],"subject":[],"published":{"date-parts":[[2021,4,30]]},"assertion":[{"value":"8 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"146"}}